Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide, Bortezomib, Dexamethasone +/- Isatuximab in Transplant-ineligible Newly Diagnosed Multiple Myeloma
NCT05272826Phase 2Recruiting
- Sponsor
- Canadian Myeloma Research Group
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Primary endpoint: Stringent Complete Response at 16 weeks. Started Dec 2024; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05272826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272826.